Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ZNTL
Strong SellSinkerZentalis Pharmaceuticals, Inc. · Healthcare · United States · $360M · Avg Vol: $4M/d
18
StockRankGet insider-trade alerts
Q
25
V
32
M
43
P/E (TTM)
—
ROE
-66.7%
D/E
0.3x
Dividend %
—
COMPANY DESCRIPTION
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 67.4M | 0 | — | — | — | 16.4M | -37.6% |
| EPS | -4.48 | -4.47 | -2.33 | -1.91 | — | -1.91 | -2.11 | -1.81 | — |
| Shares | 59.3M | 70.8M | 71.3M | 69.1M | +16.5% | — | — | — | — |
| Debt | 45.2M | 43.1M | 39.6M | 35.7M | -7.5% | 37.7M | — | — | — |
| Equity | 433.8M | 437.3M | 337.2M | 216.2M | -20.7% | — | — | — | — |
| Op CF | -163.8M | -207.8M | -170.9M | -125.2M | — | -128.1M | — | — | — |
| Inv CF | -114.2M | -44.5M | 176.6M | 131.6M | — | — | — | — | — |
| Fin CF | 261.0M | 237.3M | 0.1M | -4.3M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-27.0%
SMA 50SMA 200
Close
$3.59
RSI (14)
41.0
52W High
$6.95
From 52W High
0.5%
SCORE BREAKDOWN
Quality
25
ROIC
-60.8%12.3
ROE
-66.7%14.4
GP/Assets
—N/A
Op. Margin
0.0%38.0
FCF/Assets
-27.5%15.4
Piotroski
29.5
Int. Cover
—N/A
D/E Ratio
0.26x44.4
Current Ratio
4.82x71.2
Value
32
P/E (TTM)
—N/A
EV/EBITDA
-1.0x25.0
P/FCF
—N/A
P/B
1.6x72.0
P/S
—N/A
Div Yield
—N/A
Momentum
43
52W High %
52%25.9
RS 6M
9%73.8
SMA 50/200
1.31x93.9
EPS Rev 4W
-18.4%5.0
EPS Rev 12W
—N/A
EPS Improve
+5%25.2
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$360M
P/E (Forward)
-2.2x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ZNTL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ZNTL | Zentalis Pharmaceuticals, Inc.(you) | $360M | 18 | Strong Sell |
| IPSC | Century Therapeutics, Inc. | $367M | 17 | Strong Sell |
| VNDA | Vanda Pharmaceuticals Inc. | $320M | 18 | Strong Sell |
| DMAC | DiaMedica Therapeutics Inc. | $345M | 16 | Strong Sell |
| IMRX | Immuneering Corporation | $323M | 19 | Strong Sell |
| FULC | Fulcrum Therapeutics, Inc. | $294M | 17 | Strong Sell |
| AVIR | Atea Pharmaceuticals, Inc. | $430M | 17 | Strong Sell |
| OBIO | Orchestra BioMed Holdings, Inc. | $312M | 19 | Strong Sell |
| LRMR | Larimar Therapeutics, Inc. | $417M | 16 | Strong Sell |
| ALXO | ALX Oncology Holdings Inc. | $277M | 17 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%